Mayne Pharma Group Limited
(ASX:MYX) reports a lower net profit for FY15 with the underlying figure coming down 25 per cent to $13.4 million.
The pharmaceutical company says the year was a transformational period where the focus was on the $50 million acquisition of the Doryx brand.
The company’s second half result was far healthier than its first with revenue up 37 per cent and underlying earnings (EBITDA) up 49 per cent.
Looking forward its hoped that product acquisitions will clear the way for strong earnings growth with new products driving market penetration.
